Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Amivantamab-vmjw + Bevacizumab + Lazertinib |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Amivantamab-vmjw | Rybrevant | JNJ-61186372 | EGFR Antibody 43 MET Antibody 24 | Rybrevant (amivantamab-vmjw) is a bi-specific antibody that targets EGFR and MET, resulting in inhibition of downstream signaling and potentially leading to decreased growth of EGFR and/or MET-expressing tumors (PMID: 27216193, PMID: 32414908). Rybrevant (amivantamab-vmjw) is FDA approved for use in patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR exon 20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy (FDA.gov). |
Bevacizumab | Avastin | VEGF Antibody 10 VEGFR Inhibitor (Pan) 34 | Avastin (bevacizumab) is a monoclonal antibody that binds VEGF and inhibits binding to VEGFR, potentially resulting in decreased tumor growth (PMID: 15136787). Avastin (bevacizumab) is FDA approved for use in colorectal cancer, non-small cell lung cancer, glioblastoma, renal cell carcinoma, cervical carcinoma, and ovarian cancer, and in combination with carboplatin and paclitaxel in epithelial ovarian, fallopian tube, or primary peritoneal cancer (FDA.gov). | |
Lazertinib | GNS 1480|YH25448|JNJ-73841937|JNJ73841937|JNJ 73841937|YH 25448|YH-25448 | EGFR Inhibitor 3rd gen 25 | Lazertinib (YH25448) is an irreversible protein kinase inhibitor with selective activity against mutant EGFR, which may lead to growth inhibition of EGFR-mutant tumor cells and reduced toxicity (PMID: 30670498, PMID: 32599977). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05601973 | Phase II | Amivantamab-vmjw + Bevacizumab + Lazertinib | AMAZE-lung: Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKI | Recruiting | ITA | FRA | ESP | 5 |